Boston Scientific Corporation reported fourth‑quarter 2025 results that exceeded expectations on both revenue and earnings. Net sales rose 15.9% year‑over‑year to $5.286 billion, beating the consensus estimate of $5.27 billion by $20 million. GAAP net income reached $672 million, or $0.45 per share, while adjusted earnings per share climbed to $0.80, a $0.02 per share beat over the $0.78 consensus. The beat was driven by disciplined cost management and a favorable product mix that amplified pricing power in high‑margin cardiovascular and electrophysiology lines.
The revenue lift was largely powered by the cardiovascular segment, which generated $3.477 billion—an 18.2% increase on a reported basis—thanks to strong demand for its WATCHMAN and other interventional devices. The med‑surg segment contributed $1.809 billion, up 11.7%, supported by growth in endoscopy and urology product lines. The remaining $1.000 billion of sales came from other cardiovascular and med‑surg sub‑segments, all of which posted double‑digit growth, underscoring the company’s broad‑based demand momentum.
Operating margin slipped to 27.3% from 27.3% a year earlier, a 10‑basis‑point decline that reflects modest pricing pressure in China and higher raw‑material costs. Gross margin, however, improved to 70.7%, up 10 basis points, indicating that the company’s pricing strategy and supply‑chain efficiencies offset cost increases. The margin profile suggests that while the company is maintaining profitability, it faces headwinds that could compress future earnings if not addressed.
Management guided full‑year 2026 revenue growth to 10.5%–11.5% on a reported basis and adjusted EPS to $3.43–$3.49, a slight lift from the prior guidance of $3.40–$3.46. The guidance is below the analyst consensus midpoint of $3.47, which contributed to a sharp pre‑market decline. The company’s outlook signals confidence in its core product pipeline but also signals caution about macro‑economic and regulatory headwinds, particularly in China where tariff and pricing pressures are expected to persist.
Investors reacted sharply to the 2026 outlook, with the stock falling 9% in pre‑market trading. The market’s focus on the guidance rather than the Q4 beat reflects a prioritization of future growth expectations over current performance. Management acknowledged the headwinds, noting that tariff and pricing pressures in China will require continued innovation to protect margins, while highlighting the strength of its electrophysiology and WATCHMAN franchises as key tailwinds.
Boston Scientific also reiterated its strategic growth plan, announcing agreements to acquire Penumbra, Inc. and Valencia Technologies Corporation and completing the acquisition of Nalu Medical. The company’s product pipeline expanded with FDA and CE approvals for the FARAPOINT PFA catheter and the launch of SEISMIQ IVL and TheraSphere 360. CEO Mike Mahoney said the company’s “exceptional year” was driven by “differentiated innovation and high performance,” positioning Boston Scientific to sustain its growth trajectory into the future.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.